Urogen Pharma Says Zusduri Expected To Be Available In U.S. By July 1
Reuters
06-13
June 12 (Reuters) - Urogen Pharma Ltd :: *U.S. FDA APPROVES UROGEN’S ZUSDURI™ (MITOMYCIN) FOR INTRAVESICAL SOLUTION AS THE FIRST AND ONLY MEDICATION FOR RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (LG-IR-NMIBC) *UROGEN PHARMA LTD - ZUSDURI EXPECTED TO BE AVAILABLE IN U.S. BY JULY 1, 2025